1
|
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.
|
Blood
|
2004
|
11.07
|
2
|
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.
|
Proc Natl Acad Sci U S A
|
2012
|
7.14
|
3
|
Association of perceived medical errors with resident distress and empathy: a prospective longitudinal study.
|
JAMA
|
2006
|
5.06
|
4
|
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.
|
Blood
|
2009
|
4.74
|
5
|
Strategies for improving attendance at medical grand rounds at an academic medical center.
|
Mayo Clin Proc
|
2003
|
3.71
|
6
|
Association of resident fatigue and distress with perceived medical errors.
|
JAMA
|
2009
|
3.70
|
7
|
SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.
|
Blood
|
2007
|
3.52
|
8
|
Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).
|
J Clin Oncol
|
2012
|
3.37
|
9
|
The well-being of physicians.
|
Am J Med
|
2003
|
3.29
|
10
|
Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era.
|
J Clin Oncol
|
2009
|
3.07
|
11
|
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.
|
J Clin Oncol
|
2009
|
3.07
|
12
|
Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484.
|
J Clin Oncol
|
2004
|
2.98
|
13
|
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2008
|
2.80
|
14
|
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.
|
Blood
|
2006
|
2.63
|
15
|
Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma.
|
Blood
|
2007
|
2.31
|
16
|
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.
|
Am J Hematol
|
2010
|
2.27
|
17
|
Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2010
|
2.06
|
18
|
Anthropometric characteristics, physical activity, and risk of non-Hodgkin's lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective study.
|
Am J Epidemiol
|
2002
|
1.76
|
19
|
The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma.
|
Leuk Lymphoma
|
2012
|
1.72
|
20
|
Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome.
|
Blood
|
2004
|
1.71
|
21
|
Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival.
|
Blood
|
2007
|
1.63
|
22
|
Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.
|
J Clin Oncol
|
2005
|
1.61
|
23
|
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma.
|
Haematologica
|
2011
|
1.60
|
24
|
The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation.
|
Cancer
|
2010
|
1.59
|
25
|
NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes.
|
Blood
|
2005
|
1.59
|
26
|
GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma.
|
PLoS Genet
|
2011
|
1.58
|
27
|
Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma.
|
Cancer Cell
|
2012
|
1.54
|
28
|
Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma.
|
Clin Cancer Res
|
2013
|
1.53
|
29
|
Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma.
|
Int J Cancer
|
2003
|
1.51
|
30
|
Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).
|
Leuk Lymphoma
|
2013
|
1.51
|
31
|
Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
|
Clin Cancer Res
|
2009
|
1.48
|
32
|
18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of 'indeterminate' reports.
|
Leuk Lymphoma
|
2010
|
1.47
|
33
|
Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.
|
J Clin Oncol
|
2005
|
1.46
|
34
|
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.
|
Blood
|
2011
|
1.45
|
35
|
Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.
|
J Clin Oncol
|
2013
|
1.42
|
36
|
The clinical spectrum of Castleman's disease.
|
Am J Hematol
|
2012
|
1.41
|
37
|
Absolute lymphocyte count predicts overall survival in follicular lymphomas.
|
Br J Haematol
|
2006
|
1.36
|
38
|
Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma.
|
Blood
|
2002
|
1.34
|
39
|
Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients.
|
Br J Haematol
|
2013
|
1.34
|
40
|
GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features.
|
Blood
|
2014
|
1.32
|
41
|
Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia.
|
Br J Haematol
|
2007
|
1.32
|
42
|
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
|
Mayo Clin Proc
|
2010
|
1.32
|
43
|
SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.
|
Cancer Cell
|
2013
|
1.30
|
44
|
Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma.
|
Cancer Epidemiol Biomarkers Prev
|
2008
|
1.26
|
45
|
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.
|
J Clin Oncol
|
2014
|
1.26
|
46
|
Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma.
|
J Clin Oncol
|
2011
|
1.24
|
47
|
Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior.
|
Am J Surg Pathol
|
2005
|
1.24
|
48
|
Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.
|
Blood
|
2012
|
1.23
|
49
|
The utility of restaging bone marrow biopsy in PET-negative patients with diffuse large B-cell lymphoma and baseline bone marrow involvement.
|
Am J Hematol
|
2014
|
1.23
|
50
|
Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases?
|
Transplantation
|
2005
|
1.17
|
51
|
Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma.
|
Int J Mol Epidemiol Genet
|
2011
|
1.17
|
52
|
Natural killer/T-cell lymphoma with ocular and adnexal involvement.
|
Ophthalmology
|
2005
|
1.15
|
53
|
Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma.
|
Am J Hematol
|
2009
|
1.14
|
54
|
Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma.
|
Leuk Lymphoma
|
2012
|
1.14
|
55
|
Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma: a population-based study.
|
Cancer
|
2010
|
1.12
|
56
|
Prospective study of survival outcomes in Non-Hodgkin's lymphoma patients with rheumatoid arthritis.
|
J Clin Oncol
|
2006
|
1.12
|
57
|
Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.
|
J Clin Oncol
|
2005
|
1.11
|
58
|
Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia.
|
Cancer Epidemiol Biomarkers Prev
|
2002
|
1.09
|
59
|
Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI).
|
Br J Haematol
|
2010
|
1.06
|
60
|
A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
|
Cancer
|
2006
|
1.06
|
61
|
Germline variation in apoptosis pathway genes and risk of non-Hodgkin's lymphoma.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
1.04
|
62
|
Antioxidant intake from fruits, vegetables and other sources and risk of non-Hodgkin's lymphoma: the Iowa Women's Health Study.
|
Int J Cancer
|
2010
|
1.03
|
63
|
Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study.
|
Cytokine
|
2012
|
1.03
|
64
|
Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil.
|
Neurology
|
2005
|
1.00
|
65
|
A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32.
|
Blood
|
2011
|
0.99
|
66
|
Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas.
|
Br J Haematol
|
2007
|
0.98
|
67
|
Therapeutic options in patients with lymphoma and severe liver dysfunction.
|
Mayo Clin Proc
|
2004
|
0.97
|
68
|
If you feed them, they will come: a prospective study of the effects of complimentary food on attendance and physician attitudes at medical grand rounds at an academic medical center.
|
BMC Med Educ
|
2007
|
0.97
|
69
|
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma.
|
Br J Haematol
|
2012
|
0.97
|
70
|
Menstrual and reproductive factors and risk of non-Hodgkin lymphoma: the Iowa women's health study (United States).
|
Cancer Causes Control
|
2002
|
0.96
|
71
|
Involvement of the lacrimal drainage system by leukemia or lymphoma.
|
Ophthal Plast Reconstr Surg
|
2002
|
0.95
|
72
|
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.
|
Blood
|
2011
|
0.95
|
73
|
Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era.
|
Leuk Lymphoma
|
2005
|
0.93
|
74
|
Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma.
|
Am J Hematol
|
2011
|
0.93
|
75
|
Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma.
|
Leuk Lymphoma
|
2014
|
0.93
|
76
|
Food-frequency questionnaire-based estimates of total antioxidant capacity and risk of non-Hodgkin lymphoma.
|
Int J Cancer
|
2011
|
0.93
|
77
|
Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres.
|
Br J Haematol
|
2014
|
0.92
|
78
|
Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.
|
J Clin Oncol
|
2013
|
0.91
|
79
|
Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab.
|
Mayo Clin Proc
|
2007
|
0.91
|
80
|
Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients.
|
Am J Hematol
|
2012
|
0.91
|
81
|
Early life sun exposure, vitamin D-related gene variants, and risk of non-Hodgkin lymphoma.
|
Cancer Causes Control
|
2012
|
0.89
|
82
|
Diffuse Large B-Cell Lymphoma Version 1.2016.
|
J Natl Compr Canc Netw
|
2016
|
0.89
|
83
|
Endobronchial ultrasound and lymphoproliferative disorders: a retrospective study.
|
Ann Thorac Surg
|
2012
|
0.88
|
84
|
The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma.
|
Leuk Lymphoma
|
2012
|
0.88
|
85
|
Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma.
|
Am J Hematol
|
2012
|
0.87
|
86
|
A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era.
|
Br J Haematol
|
2014
|
0.86
|
87
|
Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494.
|
Clin Cancer Res
|
2010
|
0.86
|
88
|
A two-stage evaluation of genetic variation in immune and inflammation genes with risk of non-Hodgkin lymphoma identifies new susceptibility locus in 6p21.3 region.
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
0.86
|
89
|
Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2002
|
0.86
|
90
|
Risk of non-Hodgkin lymphoma in association with germline variation in complement genes.
|
Br J Haematol
|
2009
|
0.84
|
91
|
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.
|
Am J Hematol
|
2013
|
0.84
|
92
|
Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial.
|
Leuk Lymphoma
|
2011
|
0.83
|
93
|
CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.83
|
94
|
Paraneoplastic sarcoid-like reactions and the eye.
|
Retina
|
2015
|
0.82
|
95
|
A prospective study of the relationship between medical knowledge and professionalism among internal medicine residents.
|
Acad Med
|
2007
|
0.82
|
96
|
Current status of medical grand rounds in departments of medicine at US medical schools.
|
Mayo Clin Proc
|
2006
|
0.82
|
97
|
Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström's macroglobulinemia.
|
Clin Exp Nephrol
|
2008
|
0.81
|
98
|
The association between early life and adult body mass index and physical activity with risk of non-Hodgkin lymphoma: impact of gender.
|
Ann Epidemiol
|
2012
|
0.81
|
99
|
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.
|
J Natl Compr Canc Netw
|
2015
|
0.81
|
100
|
Trans fatty acid intake is associated with increased risk and n3 fatty acid intake with reduced risk of non-hodgkin lymphoma.
|
J Nutr
|
2013
|
0.80
|
101
|
Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
|
Am J Nephrol
|
2012
|
0.80
|
102
|
Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma.
|
Am J Hematol
|
2014
|
0.80
|
103
|
CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis.
|
Cancer Immunol Immunother
|
2013
|
0.80
|
104
|
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
|
Br J Haematol
|
2013
|
0.80
|
105
|
The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma.
|
Leuk Lymphoma
|
2006
|
0.80
|
106
|
Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493).
|
Leuk Lymphoma
|
2012
|
0.80
|
107
|
mTOR inhibitor monotherapy is insufficient to suppress viremia and disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD).
|
Am J Hematol
|
2008
|
0.80
|
108
|
Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone.
|
Leuk Lymphoma
|
2007
|
0.79
|
109
|
Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.
|
Cytokine
|
2013
|
0.78
|
110
|
FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status.
|
Leuk Lymphoma
|
2013
|
0.78
|
111
|
Treatment of late-stage Sézary syndrome with 2-Chlorodeoxyadenosine.
|
Int J Dermatol
|
2002
|
0.78
|
112
|
LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era.
|
Leuk Lymphoma
|
2012
|
0.77
|
113
|
Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma.
|
Am J Hematol
|
2015
|
0.77
|
114
|
Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort.
|
Int J Cancer
|
2013
|
0.77
|
115
|
Survival in patients with limited-stage peripheral T-cell lymphomas.
|
Leuk Lymphoma
|
2014
|
0.77
|
116
|
Patients with celiac disease and B-cell lymphoma have a better prognosis than those with T-cell lymphoma.
|
Clin Gastroenterol Hepatol
|
2010
|
0.77
|
117
|
Inherited genetic variation and overall survival following follicular lymphoma.
|
Am J Hematol
|
2012
|
0.77
|
118
|
Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors.
|
Leuk Lymphoma
|
2014
|
0.77
|
119
|
Secondary intramedullary spinal cord non-Hodgkin's lymphoma.
|
J Neurooncol
|
2011
|
0.77
|
120
|
Lymphoma-associated skin cancer: incidence, natural history, and clinical management.
|
Int J Dermatol
|
2013
|
0.77
|
121
|
Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphoma.
|
Am J Hematol
|
2014
|
0.76
|
122
|
Secondary Epstein-Barr virus associated lymphoproliferative disorder developing in a patient with angioimmunoblastic T cell lymphoma on vorinostat.
|
Am J Hematol
|
2012
|
0.76
|
123
|
Epstein-Barr virus infection as a complication of transplantation of a nerve allograft from a living related donor. Case report.
|
J Neurosurg
|
2007
|
0.76
|
124
|
Education scholarship.
|
Mayo Clin Proc
|
2006
|
0.75
|
125
|
Images and reflections from Mayo Clinic heritage.
|
Mayo Clin Proc
|
2003
|
0.75
|
126
|
Splenectomy for massive splenomegaly: long-term results and risks for mortality.
|
Ann Surg
|
2013
|
0.75
|
127
|
Images and reflections from Mayo Clinic heritage.
|
Mayo Clin Proc
|
2002
|
0.75
|
128
|
Clinical characteristics of familial vs. sporadic non-Hodgkin lymphoma in patients diagnosed at the Mayo Clinic (1986-2000).
|
Leuk Lymphoma
|
2004
|
0.75
|